203 related articles for article (PubMed ID: 21907000)
1. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
Houot R; Kohrt HE; Marabelle A; Levy R
Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
3. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
[TBL] [Abstract][Full Text] [Related]
4. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
5. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
Weiner LM; Zarou CM; O'Brien J; Ring D
J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
[TBL] [Abstract][Full Text] [Related]
6. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
Chen Z; Freedman MS
Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
[TBL] [Abstract][Full Text] [Related]
7. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.
Terunuma H; Deng X; Dewan Z; Fujimoto S; Yamamoto N
Int Rev Immunol; 2008; 27(3):93-110. PubMed ID: 18437601
[TBL] [Abstract][Full Text] [Related]
8. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
9. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils as effector cells for antibody-based immunotherapy of cancer.
van Egmond M; Bakema JE
Semin Cancer Biol; 2013 Jun; 23(3):190-9. PubMed ID: 23287459
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
12. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
[TBL] [Abstract][Full Text] [Related]
14. Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies.
Segal DM; Qian JH; Garrido MA; Perez P; Winkler DF; Wunderlich JR; Snider DP; Valdayo MJ; Titus JA
Princess Takamatsu Symp; 1988; 19():323-31. PubMed ID: 3269363
[TBL] [Abstract][Full Text] [Related]
15. [New insights into cytotoxic effector cells].
Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
[TBL] [Abstract][Full Text] [Related]
16. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
[TBL] [Abstract][Full Text] [Related]
18. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
Wesa AK; Storkus WJ
Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
[TBL] [Abstract][Full Text] [Related]
19. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
20. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]